Navigation Links
Choice of Derek H. Lee as Chief Financial and Corporate Development Officer Strengthens Talaris Advisors' Portfolio Design Business Model

Talaris to leverage Lee's venture capital expertise with more than 55 portfolio therapeutics, medical device and healthcare services companies.

Hopkinton, MA (PRWEB) March 8, 2010 -- Talaris Advisors, LLC, today announced the appointment of Derek H. Lee to the role of Chief Financial and Corporate Development Officer. Mr. Lee comes to Talaris from SV Life Sciences (SVLS), a leading healthcare venture capital firm with capital commitments of approximately $1.5 billion. He was responsible for directing strategic financial and investment planning that incorporated market considerations into the operational performance and financing requirements of more than 55 portfolio therapeutics, medical device and healthcare services companies.

"We are entering a new phase of biotech and pharma investment today where success will be determined by a company's ability to make smart analytical decisions about its drug development candidates and terminate programs early and quickly when they miss key competitive and capital indicators,” commented Mark J. Pykett, Chief Executive Officer. “In this regard, Derek brings a strong investor perspective to our operations. His experience in aligning development with exit strategies and realizing optimal exits are a key component of Talaris’ value proposition. As our Chief Financial and Corporate Development Officer, Derek's ability to conduct quantitative and qualitative analyses, identify key risks and opportunities in complex financial and valuation models, and facilitate negotiations will give us the corporate vantage point our valued clients and investors need.”

Derek brings a decade's worth of expertise in ensuring some of the best management teams in the industry achieved their investment objectives. His background includes a range of experiences, from private and public financing strategies, to M&A transactions, partnerships and deal structuring. Lee has prior experience working with the Global Healthcare Group at UBS Warburg and with the Healthcare Investment Banking Group at Salomon Smith Barney. He received his BS Finance from Bentley College.

Talaris Advisors works with biotech managers, companies and investors to optimize the use of capital and exit outcomes for drug development programs. Veteran team members, averaging 30 years of drug development experience, design and implement strategies that improve success rates, build multiple exit options and maximize investment returns for therapeutic drug assets. We align the commercial and regulatory requirements of drug candidates in development programs to reduce risk and time factors in pre-IND to Phase II proof-of-concept development, improving their odds for regulatory and commercial success. For investors, our integrated portfolio approach diversifies intrinsic investment risks. Members of the Talaris team have successfully completed more than 125 clinical studies and advanced more than 30 drug products through to the market. The company is headquartered in Hopkinton, Massachusetts. Please visit Talaris at

Media Contact:
Vicki Byatte
Talaris Advisors
Telephone: 508-497-2300 x 229    
Email: vbyatte(at)talarisadvisors(dot)com


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. BetterInvesting Magazine Releases May Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
2. USHEALTH Career Agency Announces Americas Choice
3. Study: Choice between stroke-prevention procedures influenced by patient age
4. Nurtur Acquires ActivHealth and Wellness by Choice; Gains Exclusive Partnership with Duke University Center for Living
5. PCMA: Proposed Overhaul of FEHBP Pharmacy Benefit Would Undermine Cost-Saving Tools, Reduce Choices for 8 Million Americans
6. New Online Store Makes Buying Cosmetics a Healthy Choice
7. Dr Yaghouti of Global Laser Vision Receives Patient's Choice Award for 2009
8. Summit Medical Group Physician Named "Nurses Choice: Top Doctor"
9. Healthy Choice Shatters the Winter Mealtime Rut With 11 Delicious New Frozen Entrees
10. Morrisey Associates Partners With Total Living Choices (TLC) to Provide Software Value-Add to Customers
11. Security Choice Warns Against Dangers of Carbon Monoxide
Post Your Comments:
Related Image:
Choice of Derek H. Lee as Chief Financial and Corporate Development Officer Strengthens Talaris Advisors' Portfolio Design Business Model 
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed ... 1-1 ). More than 3.7 billion people under the age of 50 – or ... to WHO's first global estimates of HSV-1 infection . , "The data shocks us ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... Secura Consultants has prided itself for not only fulfilling the needs of advisers ... solutions at an affordable price and providing top-tier customer service. However, there's always ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
(Date:11/26/2015)... ... ... Inevitably when people think Thanksgiving, they also think Holiday sales and start ... and Cyber Monday massage chair sales to receive the best pricing on ... find the best massage chair deals, they can see all of the coupons in ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology: